Pinetree Therapeutics has a total of 26 patents globally, out of which 8 have been granted. Of these 26 patents, more than 69% patents are active. The USA is where Pinetree Therapeutics has filed the maximum number of patents, followed by Europe, Australia and Canada. Parallelly, Korea (South) seems to be the main focused R&D centre and also USA is the origin country of Pinetree Therapeutics.
Pinetree Therapeutics was founded in 2019. Pinetree Therapeutics pioneers ground-breaking treatments for cancer, focusing on both traditional oncology and immuno-oncology, aiming to revolutionize cancer care through innovative therapies.
Do read about some of the most popular patents of Pinetree Therapeutics which have been covered by us in this article and also you can find Pinetree Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Pinetree Therapeutics patent portfolio.
How many patents does Pinetree Therapeutics have?
Pinetree Therapeutics has a total of 26 patents globally. These patents belong to 6 unique patent families. Out of 26 patents, 18 patents are active.
How Many Patents did Pinetree Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Pinetree Therapeutics Applications Filed | Pinetree Therapeutics Patents Granted |
| 2023 | 2 | 1 |
| 2022 | 2 | 1 |
| 2021 | 6 | 4 |
| 2020 | 1 | – |
| 2019 | 1 | 1 |
| 2018 | 4 | 1 |
| 2017 | 1 | – |
| 2016 | 8 | – |
| 2014 | 1 | – |
How many Pinetree Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Pinetree Therapeutics File in Different Countries?
Countries in which Pinetree Therapeutics Filed Patents
| Country | Patent |
| United States Of America | 10 |
| Europe (EPO) | 4 |
| Australia | 2 |
| Canada | 2 |
| Mexico | 1 |
| Denmark | 1 |
| Spain | 1 |
| Austria | 1 |
| Italy | 1 |
| Germany | 1 |
Where are Research Centers of Pinetree Therapeutics Patents Located?
What Percentage of Pinetree Therapeutics US Patent Applications Were Granted?
Pinetree Therapeutics (Excluding its subsidiaries) has filed 7 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 3 have been granted leading to a grant rate of 42.86%.
Below are the key stats of Pinetree Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Pinetree Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Jonathan P O’Brien PhD | 6 | 33.33% |
| United One Law Group Llc | 1 | 0% |
List of Pinetree Therapeutics patents
| Pinetree Therapeutics Patents | Title |
| US11548915B2 | Composition For Overcoming Resistance To Egfr-Targeting Agent |
| US10400022B2 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused With Same, And Use Thereof |
| US9975933B2 | Tumor Tissue-Penetrating Peptide Specific To Neuropilin And Fusion Protein Having Same Peptide Fused Therein |
| US20230312684A1 | Neuropilin And Angiotensin Converting Enzyme 2 Fusion Peptides For Treating Viral Infections |
| US20230257422A1 | Composition For Overcoming Resistance To Egfr-Targeting Agent |
| EP3275895B1 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused With Same, And Use Thereof |
| EP4188415A2 | Neuropilin And Angiotensin Converting Enzyme 2 Fusion Peptides For Treating Viral Infections |
| EP3978519A1 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused With Same, And Use Thereof |
| EP3680250A4 | Composition For Restraining Activity Of Regulatory T Cell, Comprising Peptide Binding Specifically To Neuropilin 1 (Nrp1) |
| ES2894299T3 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused Thereto And Use Thereof |
| DK3275895T3 | Neuropilin-1-Specific Binding Peptide, Fusion Protein Fused Thereto, And Use Thereof |
| DE602016062757T2 | Neuropilin-1-Specific Binding Peptide, Fusion Protein Fused With It And Use Thereof |
| IT202100086807T2 | Peptide Binding Specifically Neuropilin-1, Fusion Protein Fused With The Same And Their Use |
| WO2023192514A1 | Bispecific Antibodies Comprising An Nrp1 Binding Domain And Methods Of Use Thereof |
| AU2021315818A1 | Neuropilin And Angiotensin Converting Enzyme 2 Fusion Peptides For Treating Viral Infections |
| CA3187747A1 | Neuropilin And Angiotensin Converting Enzyme 2 Fusion Peptides For Treating Viral Infections |
| CA3075403A1 | Composition For Restraining Activity Of Regulatory T Cell, Comprising Peptide Binding Specifically To Neuropilin 1 (Nrp1) |
| MX2023001366A | Neuropilin And Angiotensin-Converting Enzyme 2 Fusion Peptides For The Treatment Of Viral Infections |
| US20220298220A1 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused With Same, And Use Thereof |
| US20210198340A1 | Neuropilin-1 Specific Binding Peptides And Its Fusion Protein, And Use Thereof |
| US20200362010A1 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused With Same, And Use Thereof |
| US20200276328A1 | Composition For Restraining Activity Of Regulatory T Cell, Comprising Peptide Binding Specifically To Neuropilin 1 (Nrp1) |
| US20200010526A1 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused With Same, And Use Thereof |
| WO2022026943A3 | Neuropilin And Angiotensin Converting Enzyme 2 Fusion Peptides For Treating Viral Infections |
| AT1423721T | Neuropilin-1-Spezifisches Bindungspeptid, Damit Fusioniertes Fusionsprotein Und Verwendung Davon |
| AU2018327940A1 | Composition For Restraining Activity Of Regulatory T Cell, Comprising Peptide Binding Specifically To Neuropilin 1 (Nrp1) |
What are Pinetree Therapeutics key innovation segments?
What Technologies are Covered by Pinetree Therapeutics?
The chart below distributes patents filed by Pinetree Therapeutics